Bowel Function and Global Quality of Life by Rectal Status After Neoadjuvant Treatment for Rectal Cancer: A Retrospective Cohort Study

Background: Organ preservation is expected to spare bowel function, but whether that gain is reflected in how patients rate their own quality of life is unclear. Methods: A retrospective comparative cohort study was conducted at a single tertiary center in 2021–2024. Of 52 patients with locally advanced rectal cancer receiving neoadjuvant treatment, 31 entered the watch-and-wait arm and 21 formed a comparator arm. Bowel function (LARS, Wexner, Vaizey) and quality of life (EORTC QLQ-C30, QLQ-CR29) were compared between TME-free (n = 13) and TME respondents (n = 20). Bowel function was the primary outcome family; the rest are exploratory and uncorrected for multiplicity. Results: Bowel function differed widely: median LARS 16.0 vs. 35.5, Wexner 2.0 vs. 11.5, Vaizey 2.0 vs. 15.0 (all p < 0.001), with major LARS in 15.4% vs. 90.0% (p < 0.001). No difference in global quality of life was detected (58.3 vs. 54.2; p = 0.615), or in physical or role functioning. Body image and six colorectal symptom scales favored the TME-free group, whereas blood or mucus, abdominal pain, buttock pain, and bloating showed none. Groups reflect rectal status at assessment, not randomized strategy. Eleven of 17 comparator patients had a coloanal anastomosis, nine of them at the anal verge itself, widening the functional contrast. Freedom from any rectal surgery was 74.2% (23 of 31) in the full arm and 68.4% (13 of 19) per protocol; median follow-up was 15 months. Conclusions: Bowel function was substantially better in TME-free respondents, while this small cross-sectional study did not detect a global quality-of-life difference. Its magnitude and generalizability await larger cohorts.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Medicine
Published
2026-11-19
DOI
https://doi.org/10.3390/jcm15229082
Primary Topic
Colorectal Cancer Surgical Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Bowel Function and Global Quality of Life by Rectal Status After Neoadjuvant Treatment for Rectal Cancer: A Retrospective Cohort Study

Mustafa Öncel, Zenciroglu Mahmut, Oğuzhan Hakan Topgül, Caglar Kazim Pekuz et al.
Journal of Clinical Medicine
Colorectal Cancer Surgical Treatments
article

Bowel Function and Global Quality of Life by Rectal Status After Neoadjuvant Treatment for Rectal Cancer: A Retrospective Cohort Study

Mustafa Öncel, Zenciroglu Mahmut, Oğuzhan Hakan Topgül, Caglar Kazim Pekuz, Perya Abbasoglu
article en

Abstract

Background: Organ preservation is expected to spare bowel function, but whether that gain is reflected in how patients rate their own quality of life is unclear. Methods: A retrospective comparative cohort study was conducted at a single tertiary center in 2021–2024. Of 52 patients with locally advanced rectal cancer receiving neoadjuvant treatment, 31 entered the watch-and-wait arm and 21 formed a comparator arm. Bowel function (LARS, Wexner, Vaizey) and quality of life (EORTC QLQ-C30, QLQ-CR29) were compared between TME-free (n = 13) and TME respondents (n = 20). Bowel function was the primary outcome family; the rest are exploratory and uncorrected for multiplicity. Results: Bowel function differed widely: median LARS 16.0 vs. 35.5, Wexner 2.0 vs. 11.5, Vaizey 2.0 vs. 15.0 (all p < 0.001), with major LARS in 15.4% vs. 90.0% (p < 0.001). No difference in global quality of life was detected (58.3 vs. 54.2; p = 0.615), or in physical or role functioning. Body image and six colorectal symptom scales favored the TME-free group, whereas blood or mucus, abdominal pain, buttock pain, and bloating showed none. Groups reflect rectal status at assessment, not randomized strategy. Eleven of 17 comparator patients had a coloanal anastomosis, nine of them at the anal verge itself, widening the functional contrast. Freedom from any rectal surgery was 74.2% (23 of 31) in the full arm and 68.4% (13 of 19) per protocol; median follow-up was 15 months. Conclusions: Bowel function was substantially better in TME-free respondents, while this small cross-sectional study did not detect a global quality-of-life difference. Its magnitude and generalizability await larger cohorts.

Journal of Clinical MedicineVol. 15(22)
Istanbul Medipol University (TR)
Colorectal Cancer Surgical Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon